TuisJNJ • ETR
add
Johnson & Johnson
Vorige sluiting
€147,68
Dagwisseling
€147,14 - €148,42
Jaarwisseling
€132,78 - €154,00
Markkapitalisasie
385,53 mjd USD
Gemiddelde volume
2,23 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 22,47 mjd | 5,25% |
Bedryfskoste | 10,20 mjd | 18,80% |
Netto inkomste | 2,69 mjd | -89,65% |
Netto winsgrens | 11,99 | -90,16% |
Wins per aandeel | 2,42 | -9,02% |
EBITDA | 7,36 mjd | -10,41% |
Effektiewe belastingkoers | 19,29% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 20,30 mjd | -13,67% |
Totale bates | 178,29 mjd | 7,36% |
Totale aanspreeklikheid | 108,13 mjd | 14,02% |
Totale ekwiteit | 70,16 mjd | — |
Uitstaande aandele | 2,41 mjd | — |
Prys om te bespreek | 5,07 | — |
Opbrengs op bates | 7,66% | — |
Opbrengs op kapitaal | 12,58% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 2,69 mjd | -89,65% |
Kontant van bedrywe | 7,99 mjd | — |
Kontant van beleggings | -3,13 mjd | — |
Kontant van finansiering | -9,88 mjd | — |
Netto kontantverandering | -4,90 mjd | — |
Beskikbare kontantvloei | 5,50 mjd | — |
Meer oor
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 40 on the 2023 Fortune 500 list of the largest United States corporations. In 2023, the company was ranked 40th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 130,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato.
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue. The company is exclusively focused on developing and producing pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA. Wikipedia
Gestig
Jan. 1886
Webwerf
Werknemers
131 900